Recognition highlights Prenosis’ leadership in integrated diagnostics and therapeutics and its mission to bring clarity to critical care decisions CHICAGO, IL – September 15, 2025 – Prenosis has been selected as a quarterfinalist for the 2025 Digital Health Hub...
Sepsis ImmunoScore Named Honoree in Fast Company’s 2025 World Changing Ideas Awards
Annual Awards Recognize Innovative Companies and Projects Addressing the World’s Most Urgent Challenges CHICAGO, IL [June 10, 2025] — Prenosis is proud to announce that Sepsis ImmunoScore™ has been named an honoree of Fast Company ’s 202 5 World Changing Ideas...
High-Profile Start-Ups Inato And Prenosis Show AI ‘Best Practice’
Article originally published in Forbes on May 22, 2025 Prenosis featured in article by author Michael L. Millenson, covering innovations at the 2025 MedCity INVEST conference in Chicago. “Treating artificial intelligence as just one ingredient in a business...
Bobby Reddy, Jr. Named to TIME’s 2025 TIME100 Health List
Prenosis CEO and co-founder honored as one of the 100 most influential people in global health this year CHICAGO, IL – May 8, 2025 – Prenosis, Inc., a leader in precision diagnostics powered by artificial intelligence, today announced that its CEO and co-founder,...
Study published in the New England Journal of Medicine AI Concludes that the Sepsis ImmunoScore™, the First FDA-Authorized AI Tool for Sepsis, has both significant Diagnostic and Predictive Power
Groundbreaking NEJM AI Study Highlights the Ability of Prenosis’ Sepsis ImmunoScore™ to Holistically Predict Adverse Outcomes, Ushering in a New Era of Predictive Sepsis Tools Powered by AI CHICAGO , Dec. 4, 2024 /PRNewswire/ — A new study published in the...
Sepsis ImmunoScore™ Named a TIME Best Invention of 2024
Prenosis, a Leader in AI-Driven Precision Medicine, Wins Prestigious TIME Award for Transforming Sepsis Diagnosis with Its FDA-Authorized Sepsis ImmunoScore™ CHICAGO , Oct. 30, 2024 /PRNewswire/ — Today, Prenosis Inc.’s Sepsis ImmunoScore™ was named one of...
Sepsis ImmunoScore® Featured in JAMA
In a recent article titled “FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine,” published in JAMA by three senior FDA officials, Prenosis’ Sepsis ImmunoScore® was highlighted as a pivotal example of an AI...
Prenosis CEO Bobby Reddy, Jr. Recognized Among Crain’s Chicago 40 Under 40
Bobby Reddy, Jr., Co-Founder and CEO of Prenosis, has been named one of Crain’s Chicago Business 40 Under 40 for his visionary work in precision diagnostics and AI innovation. Under Bobby’s leadership, Prenosis has developed the Sepsis ImmunoScore™, the first...
Bobby Reddy, Jr. Discusses the Transformative Impact of AI on Sepsis Care–NewsNation Now
Bobby Reddy, Jr., Co-founder and CEO of Prenosis, appeared live on NewsNation Now for an in-depth, one-on-one interview about the transformative role of artificial intelligence in sepsis care. Airing just days after the FDA authorized the Sepsis ImmunoScore™, the...
Roche to distribute Prenosis’ AI sepsis detection tool in US–MedTech Dive
MedTech Dive, a trusted source for news and analysis in the medical technology industry, reports on Roche’s partnership with Prenosis. The Sepsis ImmunoScore™, a groundbreaking AI-powered tool, is available on Roche’s Navify Algorithm Suite, marking a...